Teva and Active Signs Agreement to Study Laquinimod as Treatment for Neurological Disease
FREMONT, CA: Teva Pharmaceutical, a provider of pharmaceutical drugs for developing high-quality healthcare, and Active Biotech, a biotech company, announce that they will be expanding the laquinimod clinical development program by initiating the ARPEGGIO trial that analyzes laquinimod’s potential to treat primary progressive multiple sclerosis (PPMS). Teva also initiates LEGATO-HD trial for evaluating laquinimod in Huntington’s disease.
Laquinimod is a compound under development for the treatment of autoimmune diseases including PPMS, Huntington’s disease, Crohn's disease and Lupus. Active Biotech already signed an agreement with Teva Pharmaceutical to develop and commercialize laquinimod.
Through ARPEGGIO study, experts will analyze the efficacy, safety and tolerability of laquinimod in PPMS, a neurological disorder where the nerves of spinal cord is affected that leads to trouble balancing, walking problem and weak legs.
The LEGATO-HD study will provide the full evaluation of capacity, safety and tolerability of once-daily oral laquinimod while treating patient affected by Huntington’s disease. Huntington’s disease is a neurodegenerative genetic disorder that affects muscle coordination and causes for cognitive decline and behavioral symptoms. The primary endpoint for this study is defined as well as changed from baseline in the Unified Huntington's Disease Rating Scale-Total Motor Scale (UHDRS-TMS) that is the sum of all UHDRS-TMS sub-items after 12 months of treatment.